search
Back to results

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
linagliptin2.5mg/metformin1000mg
linagliptin2.5mg/metformin1000mg
linagliptin 5mg
Metformin 500mg
linagliptin2.5mg/metformin500mg
linagliptin2.5mg/metformin500mg
linagliptin 5mg
Metformin 1000mg
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Diagnosis of Type 2 diabetes mellitus(T2DM) prior to informed consent
  2. Male and female patients on diet and exercise regimen who are drug-naïve
  3. Glycosylated haemoglobin A1c (HbA1c) at V1a >/=7.5 %<11% for main group and HbA1c >/= 11.0 % for the additional parallel group
  4. Age >/= 18 and </= 80 years at Visit 1a (Screening)
  5. Body Mass Index(BMI)</ = 40 kg/m2 at Visit 1a (Screening)
  6. Signed and dated written informed consent by date of Visit 1a in accordance with good clinical practice(GCP) and local legislation

Exclusion criteria:

  1. Uncontrolled hyperglycaemia required for rescue medication during placebo run-in phase
  2. In main group, the patients with investigational medicinal product(IMP) compliance < 80 % or >120 % during 2 weeks placebo run in period
  3. Acute coronary syndrome stroke or Transient ischaemic attack (TIA) within 3 months prior to randomisation
  4. Impaired hepatic function, defined by serum levels of either Alanine aminotransferase(ALT) ,Aspartate aminotransferase(AST), or alkaline phosphatase (AP) above 3 x upper limit of normal (ULN) ,or total bilirubin above 1.5 x ULN as determined at Visit 1a
  5. Known hypersensitivity or allergy to linagliptin or its excipients or metformin or placebo
  6. Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening
  7. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.
  8. Concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form or during the trial.
  9. Pre-menopausal women (last menstruation </= 1 year prior to informed consent) who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study
  10. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.
  11. Renal failure or renal impairment at Visit 1a (screening) with an Estimated Glomerular Filtration Rate(eGFR) < 60 ml/min
  12. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption
  13. Dehydration by clinical judgement of the investigator
  14. Clinical detected unstable or acute congestive heart failure
  15. Acute or chronic metabolic acidosis (present in patient history)
  16. Hereditary galactose intolerance
  17. Known history of pancreatitis and chronic pancreatitis
  18. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within last 5 years.
  19. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial at the discretion of investigator

Sites / Locations

  • 1288.18.86001 Boehringer Ingelheim Investigational Site
  • 1288.18.86002 Boehringer Ingelheim Investigational Site
  • 1288.18.86003 Boehringer Ingelheim Investigational Site
  • 1288.18.86004 Boehringer Ingelheim Investigational Site
  • 1288.18.86046 Boehringer Ingelheim Investigational Site
  • 1288.18.86019 Boehringer Ingelheim Investigational Site
  • 1288.18.86020 Boehringer Ingelheim Investigational Site
  • 1288.18.86028 Boehringer Ingelheim Investigational Site
  • 1288.18.86029 Boehringer Ingelheim Investigational Site
  • 1288.18.86050 Boehringer Ingelheim Investigational Site
  • 1288.18.86045 Boehringer Ingelheim Investigational Site
  • 1288.18.86042 Boehringer Ingelheim Investigational Site
  • 1288.18.86023 Boehringer Ingelheim Investigational Site
  • 1288.18.86009 Boehringer Ingelheim Investigational Site
  • 1288.18.86010 Boehringer Ingelheim Investigational Site
  • 1288.18.86012 Boehringer Ingelheim Investigational Site
  • 1288.18.86047 Boehringer Ingelheim Investigational Site
  • 1288.18.86032 Boehringer Ingelheim Investigational Site
  • 1288.18.86016 Boehringer Ingelheim Investigational Site
  • 1288.18.86017 Boehringer Ingelheim Investigational Site
  • 1288.18.86026 Boehringer Ingelheim Investigational Site
  • 1288.18.86034 Boehringer Ingelheim Investigational Site
  • 1288.18.86039 Boehringer Ingelheim Investigational Site
  • 1288.18.86035 Boehringer Ingelheim Investigational Site
  • 1288.18.86036 Boehringer Ingelheim Investigational Site
  • 1288.18.86006 Boehringer Ingelheim Investigational Site
  • 1288.18.86007 Boehringer Ingelheim Investigational Site
  • 1288.18.86008 Boehringer Ingelheim Investigational Site
  • 1288.18.86013 Boehringer Ingelheim Investigational Site
  • 1288.18.86022 Boehringer Ingelheim Investigational Site
  • 1288.18.86014 Boehringer Ingelheim Investigational Site
  • 1288.18.86015 Boehringer Ingelheim Investigational Site
  • 1288.18.86038 Boehringer Ingelheim Investigational Site
  • 1288.18.86049 Boehringer Ingelheim Investigational Site
  • 1288.18.86033 Boehringer Ingelheim Investigational Site
  • 1288.18.86024 Boehringer Ingelheim Investigational Site
  • 1288.18.86025 Boehringer Ingelheim Investigational Site
  • 1288.18.86030 Boehringer Ingelheim Investigational Site
  • 1288.18.60004 Boehringer Ingelheim Investigational Site
  • 1288.18.60002 Boehringer Ingelheim Investigational Site
  • 1288.18.60005 Boehringer Ingelheim Investigational Site
  • 1288.18.60007 Boehringer Ingelheim Investigational Site
  • 1288.18.60001 Boehringer Ingelheim Investigational Site
  • 1288.18.60006 Boehringer Ingelheim Investigational Site
  • 1288.18.60008 Boehringer Ingelheim Investigational Site
  • 1288.18.60003 Boehringer Ingelheim Investigational Site
  • 1288.18.63003 Boehringer Ingelheim Investigational Site
  • 1288.18.63007 Boehringer Ingelheim Investigational Site
  • 1288.18.63002 Boehringer Ingelheim Investigational Site
  • 1288.18.63001 Boehringer Ingelheim Investigational Site
  • 1288.18.63008 Boehringer Ingelheim Investigational Site
  • 1288.18.63006 Boehringer Ingelheim Investigational Site
  • 1288.18.63005 Boehringer Ingelheim Investigational Site
  • 1288.18.84003 Boehringer Ingelheim Investigational Site
  • 1288.18.84001 Boehringer Ingelheim Investigational Site
  • 1288.18.84002 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Active Comparator

Arm Label

linagliptin2.5mg / metformin500mg BID

linagliptin2.5mg / metformin1000mg BID

metformin 500mg BID

metformin 1000mg BID

linagliptin 5 mg QD

Arm Description

patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID

patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID

patient to receive a tablet containing metformin 500mg BID

patient to receive a tablet containing metformin 1000mg BID

patient to receive a tablet containing linagliptin 5mg once daily

Outcomes

Primary Outcome Measures

The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group
The change from baseline in HbA1c after 24 weeks of treatment in main group. The mean was adjusted by baseline HbA1c and treatment group.
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC)
The change from baseline in HbA1c after 24 weeks of treatment in main group. Only subjects from the FAS with measured HbA1c values (observed cases [OC]) were considered. The mean was adjusted by treatment, baseline HbA1c, week and treatment*week. The sensitivity analysis was added as the primary analysis failed with borderline results.
The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG
The change from baseline in HbA1c after 12 weeks of treatment in additional parallel group (APG) The mean was adjusted by baseline HbA1c and treatment group.

Secondary Outcome Measures

The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group
The occurrence of treat to target efficacy response in terms of HbA1c < 7.0 % after 24 weeks of treatment in main group.
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG
The occurrence of treat to target efficacy response in terms of HbA1c < 7.0 % after 12 weeks of treatment in APG.
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group
The occurrence of treat to target efficacy response in terms of HbA1c < 6.5% after 24 weeks of treatment in main group.
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG
The occurrence of treat to target efficacy response in terms of HbA1c < 6.5% after 12 weeks of treatment in APG.
The Occurrence of Relative Efficacy Response in Main Group
The occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment) in main group
The Occurrence of Relative Efficacy Response in APG
The Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 12 Weeks of Treatment) in APG
The Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group
The change in fasting plasma glucose (FPG) from baseline after 24 weeks of treatment in main group. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.
The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group
The frequency of patients with use of rescue therapy during 24 week treatment period in main group. For this analysis the main group contrast 'Metformin 1000mg BID, Linagliptin 2.5mg / Metformin 1000mg BID' could not be analysed due to lack of events in the Metformin 1000mg BID group.
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG.

Full Information

First Posted
October 16, 2012
Last Updated
April 8, 2015
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01708902
Brief Title
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
Official Title
A Phase III Randomised, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Fix Dose Combination of Linagliptin 2.5 mg + Metformin 500 mg, or of Linagliptin 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg, Twice Daily), and Linagliptin (5.0 mg, Once Daily) Over 24 Weeks in Treatment naïve Type 2 Diabetic Patients With Insufficient Glycaemic Control
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company

4. Oversight

5. Study Description

Brief Summary
Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
Double
Allocation
Randomized
Enrollment
876 (Actual)

8. Arms, Groups, and Interventions

Arm Title
linagliptin2.5mg / metformin500mg BID
Arm Type
Experimental
Arm Description
patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
Arm Title
linagliptin2.5mg / metformin1000mg BID
Arm Type
Experimental
Arm Description
patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
Arm Title
metformin 500mg BID
Arm Type
Active Comparator
Arm Description
patient to receive a tablet containing metformin 500mg BID
Arm Title
metformin 1000mg BID
Arm Type
Active Comparator
Arm Description
patient to receive a tablet containing metformin 1000mg BID
Arm Title
linagliptin 5 mg QD
Arm Type
Active Comparator
Arm Description
patient to receive a tablet containing linagliptin 5mg once daily
Intervention Type
Drug
Intervention Name(s)
linagliptin2.5mg/metformin1000mg
Intervention Description
linagliptin2.5mg/metformin1000mg BID
Intervention Type
Drug
Intervention Name(s)
linagliptin2.5mg/metformin1000mg
Intervention Description
linagliptin2.5mg/metformin1000mg BID
Intervention Type
Drug
Intervention Name(s)
linagliptin 5mg
Intervention Description
linagliptin 5mg once daily
Intervention Type
Drug
Intervention Name(s)
Metformin 500mg
Intervention Description
Metformin 500mg BID
Intervention Type
Drug
Intervention Name(s)
linagliptin2.5mg/metformin500mg
Intervention Description
linagliptin2.5mg/metformin500mg BID
Intervention Type
Drug
Intervention Name(s)
linagliptin2.5mg/metformin500mg
Intervention Description
linagliptin2.5mg/metformin500mg BID
Intervention Type
Drug
Intervention Name(s)
linagliptin 5mg
Intervention Description
linagliptin 5mg once daily
Intervention Type
Drug
Intervention Name(s)
Metformin 1000mg
Intervention Description
Metformin 1000mg BID
Primary Outcome Measure Information:
Title
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group
Description
The change from baseline in HbA1c after 24 weeks of treatment in main group. The mean was adjusted by baseline HbA1c and treatment group.
Time Frame
Baseline and week 24
Title
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC)
Description
The change from baseline in HbA1c after 24 weeks of treatment in main group. Only subjects from the FAS with measured HbA1c values (observed cases [OC]) were considered. The mean was adjusted by treatment, baseline HbA1c, week and treatment*week. The sensitivity analysis was added as the primary analysis failed with borderline results.
Time Frame
Baseline and week 24
Title
The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG
Description
The change from baseline in HbA1c after 12 weeks of treatment in additional parallel group (APG) The mean was adjusted by baseline HbA1c and treatment group.
Time Frame
Baseline and week 12
Secondary Outcome Measure Information:
Title
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group
Description
The occurrence of treat to target efficacy response in terms of HbA1c < 7.0 % after 24 weeks of treatment in main group.
Time Frame
Week 24 (after first drug administration)
Title
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG
Description
The occurrence of treat to target efficacy response in terms of HbA1c < 7.0 % after 12 weeks of treatment in APG.
Time Frame
Week 12 (after first drug administration)
Title
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group
Description
The occurrence of treat to target efficacy response in terms of HbA1c < 6.5% after 24 weeks of treatment in main group.
Time Frame
Week 24 (after first drug administration)
Title
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG
Description
The occurrence of treat to target efficacy response in terms of HbA1c < 6.5% after 12 weeks of treatment in APG.
Time Frame
Week 12 (after first drug administration)
Title
The Occurrence of Relative Efficacy Response in Main Group
Description
The occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment) in main group
Time Frame
From baseline until week 24
Title
The Occurrence of Relative Efficacy Response in APG
Description
The Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 12 Weeks of Treatment) in APG
Time Frame
From baseline until week 12
Title
The Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group
Description
The change in fasting plasma glucose (FPG) from baseline after 24 weeks of treatment in main group. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.
Time Frame
Baseline and week 24
Title
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG
Description
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.
Time Frame
Baseline and week 12
Title
The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group
Description
The frequency of patients with use of rescue therapy during 24 week treatment period in main group. For this analysis the main group contrast 'Metformin 1000mg BID, Linagliptin 2.5mg / Metformin 1000mg BID' could not be analysed due to lack of events in the Metformin 1000mg BID group.
Time Frame
From baseline until week 24
Title
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG
Description
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG.
Time Frame
From baseline until week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Diagnosis of Type 2 diabetes mellitus(T2DM) prior to informed consent Male and female patients on diet and exercise regimen who are drug-naïve Glycosylated haemoglobin A1c (HbA1c) at V1a >/=7.5 %<11% for main group and HbA1c >/= 11.0 % for the additional parallel group Age >/= 18 and </= 80 years at Visit 1a (Screening) Body Mass Index(BMI)</ = 40 kg/m2 at Visit 1a (Screening) Signed and dated written informed consent by date of Visit 1a in accordance with good clinical practice(GCP) and local legislation Exclusion criteria: Uncontrolled hyperglycaemia required for rescue medication during placebo run-in phase In main group, the patients with investigational medicinal product(IMP) compliance < 80 % or >120 % during 2 weeks placebo run in period Acute coronary syndrome stroke or Transient ischaemic attack (TIA) within 3 months prior to randomisation Impaired hepatic function, defined by serum levels of either Alanine aminotransferase(ALT) ,Aspartate aminotransferase(AST), or alkaline phosphatase (AP) above 3 x upper limit of normal (ULN) ,or total bilirubin above 1.5 x ULN as determined at Visit 1a Known hypersensitivity or allergy to linagliptin or its excipients or metformin or placebo Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator. Concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form or during the trial. Pre-menopausal women (last menstruation </= 1 year prior to informed consent) who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent. Renal failure or renal impairment at Visit 1a (screening) with an Estimated Glomerular Filtration Rate(eGFR) < 60 ml/min Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption Dehydration by clinical judgement of the investigator Clinical detected unstable or acute congestive heart failure Acute or chronic metabolic acidosis (present in patient history) Hereditary galactose intolerance Known history of pancreatitis and chronic pancreatitis Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within last 5 years. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial at the discretion of investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1288.18.86001 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1288.18.86002 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1288.18.86003 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1288.18.86004 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1288.18.86046 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1288.18.86019 Boehringer Ingelheim Investigational Site
City
Changchun
Country
China
Facility Name
1288.18.86020 Boehringer Ingelheim Investigational Site
City
Changchun
Country
China
Facility Name
1288.18.86028 Boehringer Ingelheim Investigational Site
City
Changsha
Country
China
Facility Name
1288.18.86029 Boehringer Ingelheim Investigational Site
City
Changsha
Country
China
Facility Name
1288.18.86050 Boehringer Ingelheim Investigational Site
City
Changsha
Country
China
Facility Name
1288.18.86045 Boehringer Ingelheim Investigational Site
City
Chengdu
Country
China
Facility Name
1288.18.86042 Boehringer Ingelheim Investigational Site
City
Chongqing
Country
China
Facility Name
1288.18.86023 Boehringer Ingelheim Investigational Site
City
Dalian
Country
China
Facility Name
1288.18.86009 Boehringer Ingelheim Investigational Site
City
Guangzhou
Country
China
Facility Name
1288.18.86010 Boehringer Ingelheim Investigational Site
City
Guangzhou
Country
China
Facility Name
1288.18.86012 Boehringer Ingelheim Investigational Site
City
Guangzhou
Country
China
Facility Name
1288.18.86047 Boehringer Ingelheim Investigational Site
City
Haerbin
Country
China
Facility Name
1288.18.86032 Boehringer Ingelheim Investigational Site
City
Hefei
Country
China
Facility Name
1288.18.86016 Boehringer Ingelheim Investigational Site
City
Hengshui
Country
China
Facility Name
1288.18.86017 Boehringer Ingelheim Investigational Site
City
Jinan
Country
China
Facility Name
1288.18.86026 Boehringer Ingelheim Investigational Site
City
Lanzhou
Country
China
Facility Name
1288.18.86034 Boehringer Ingelheim Investigational Site
City
Nan Ning
Country
China
Facility Name
1288.18.86039 Boehringer Ingelheim Investigational Site
City
Nanchang
Country
China
Facility Name
1288.18.86035 Boehringer Ingelheim Investigational Site
City
Nanjing
Country
China
Facility Name
1288.18.86036 Boehringer Ingelheim Investigational Site
City
Nanjing
Country
China
Facility Name
1288.18.86006 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
1288.18.86007 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
1288.18.86008 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
1288.18.86013 Boehringer Ingelheim Investigational Site
City
Shantou
Country
China
Facility Name
1288.18.86022 Boehringer Ingelheim Investigational Site
City
Shenyang
Country
China
Facility Name
1288.18.86014 Boehringer Ingelheim Investigational Site
City
Shijiazhuang
Country
China
Facility Name
1288.18.86015 Boehringer Ingelheim Investigational Site
City
Shijiazhuang
Country
China
Facility Name
1288.18.86038 Boehringer Ingelheim Investigational Site
City
Suzhou
Country
China
Facility Name
1288.18.86049 Boehringer Ingelheim Investigational Site
City
Wuhan
Country
China
Facility Name
1288.18.86033 Boehringer Ingelheim Investigational Site
City
Wuhu
Country
China
Facility Name
1288.18.86024 Boehringer Ingelheim Investigational Site
City
Xi'An
Country
China
Facility Name
1288.18.86025 Boehringer Ingelheim Investigational Site
City
Xi'An
Country
China
Facility Name
1288.18.86030 Boehringer Ingelheim Investigational Site
City
Yueyang
Country
China
Facility Name
1288.18.60004 Boehringer Ingelheim Investigational Site
City
Kelantan
Country
Malaysia
Facility Name
1288.18.60002 Boehringer Ingelheim Investigational Site
City
Melaka
Country
Malaysia
Facility Name
1288.18.60005 Boehringer Ingelheim Investigational Site
City
Negeri Sembilan
Country
Malaysia
Facility Name
1288.18.60007 Boehringer Ingelheim Investigational Site
City
Negeri Sembilan
Country
Malaysia
Facility Name
1288.18.60001 Boehringer Ingelheim Investigational Site
City
Perak
Country
Malaysia
Facility Name
1288.18.60006 Boehringer Ingelheim Investigational Site
City
Perak
Country
Malaysia
Facility Name
1288.18.60008 Boehringer Ingelheim Investigational Site
City
Putrajaya
Country
Malaysia
Facility Name
1288.18.60003 Boehringer Ingelheim Investigational Site
City
Selangor
Country
Malaysia
Facility Name
1288.18.63003 Boehringer Ingelheim Investigational Site
City
Cebu City
Country
Philippines
Facility Name
1288.18.63007 Boehringer Ingelheim Investigational Site
City
Cebu
Country
Philippines
Facility Name
1288.18.63002 Boehringer Ingelheim Investigational Site
City
Makati City
Country
Philippines
Facility Name
1288.18.63001 Boehringer Ingelheim Investigational Site
City
Manila
Country
Philippines
Facility Name
1288.18.63008 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1288.18.63006 Boehringer Ingelheim Investigational Site
City
Surigao
Country
Philippines
Facility Name
1288.18.63005 Boehringer Ingelheim Investigational Site
City
Tagum City
Country
Philippines
Facility Name
1288.18.84003 Boehringer Ingelheim Investigational Site
City
Hanoi
Country
Vietnam
Facility Name
1288.18.84001 Boehringer Ingelheim Investigational Site
City
Ho Chi Minh City
Country
Vietnam
Facility Name
1288.18.84002 Boehringer Ingelheim Investigational Site
City
Ho Chi Minh City
Country
Vietnam

12. IPD Sharing Statement

Citations:
PubMed Identifier
32328953
Citation
Lv Q, Shen J, Miao L, Ye B, Schepers C, Plat A, Shi Y. Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c </= 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials. Diabetes Ther. 2020 Jun;11(6):1317-1330. doi: 10.1007/s13300-020-00819-9. Epub 2020 Apr 23.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/
Description
Related Info

Learn more about this trial

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

We'll reach out to this number within 24 hrs